Company: CMND
Filing Date: 2025-09-19
Form Type: F-1
Source: 0001213900-25-089545
Chunk: 47

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-19
Form: F-1
Chunk 47
---
 that the CLA Investors purchase additional Promissory Notes in the aggregate
principal amount of $2,500,000 for a purchase price of $2,250,000 during each subsequent three month period such that the aggregate principal
amount of such additional Promissory Notes is $7.5 million for a purchase price of $6.75 million.

The
privately placed securities above were offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2)
of the Securities Act and Rule 506 of Regulation D promulgated thereunder since, among other things, the transactions did not involve
a public offering and the securities were acquired for investment purposes only and not with a view to or for sale in connection with
any distribution thereof.

Additionally, since January
2022, we have granted share options and RSU’s to employees, directors, consultants and service providers under our Executive Stock
Option and Restricted Share Unit Plans. There are currently an aggregate of 151,813 stock options and RSU’s outstanding, with exercise
prices ranging from $23.40 to $646.74 per share.

Item 8. Exhibits and Financial Statement Schedules.

(a) Exhibits.See the
Exhibit Index attached to this registration statement, which is incorporated by reference herein.

(b) Financial Statement Schedules. Schedules not listed above have been omitted because the information required to be set forth therein is not applicable
or is shown in the financial statements or notes thereto.

Item 9. Undertakings.

| (a) | The undersigned Registrant hereby undertakes: |

| (1) | To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: |

| i. | To include any prospectus required by section 10(a)(3) of the Securities Act; |

| ii. | To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes